Supernus Pharmaceuticals EPS - Earnings per Share 2011-2024 | SUPN

Supernus Pharmaceuticals eps - earnings per share from 2011 to 2024. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Supernus Pharmaceuticals Annual EPS
2023 $0.02
2022 $1.04
2021 $0.98
2020 $2.36
2019 $2.10
2018 $2.05
2017 $1.08
2016 $1.76
2015 $0.28
2014 $-0.26
2013 $-2.90
2012 $-2.72
2011 $31.39
2010 $-26.38
Supernus Pharmaceuticals Quarterly EPS
2024-09-30 $0.69
2024-06-30 $0.36
2024-03-31 $0.00
2023-12-31 $0.04
2023-09-30 $-0.29
2023-06-30 $-0.02
2023-03-31 $0.29
2022-12-31 $0.44
2022-09-30 $0.03
2022-06-30 $0.14
2022-03-31 $0.43
2021-12-31 $0.04
2021-09-30 $0.40
2021-06-30 $0.43
2021-03-31 $0.11
2020-12-31 $0.57
2020-09-30 $0.74
2020-06-30 $0.65
2020-03-31 $0.40
2019-12-31 $0.61
2019-09-30 $0.54
2019-06-30 $0.61
2019-03-31 $0.34
2018-12-31 $0.47
2018-09-30 $0.52
2018-06-30 $0.57
2018-03-31 $0.49
2017-12-31 $0.28
2017-09-30 $0.29
2017-06-30 $0.32
2017-03-31 $0.19
2016-12-31 $0.32
2016-09-30 $1.18
2016-06-30 $0.18
2016-03-31 $0.08
2015-12-31 $0.14
2015-09-30 $0.08
2015-06-30 $0.04
2015-03-31 $0.02
2014-12-31 $0.10
2014-09-30 $-0.06
2014-06-30 $0.08
2014-03-31 $-0.38
2013-12-31 $-0.63
2013-09-30 $-0.78
2013-06-30 $-0.89
2013-03-31 $-0.60
2012-12-31 $4.49
2012-09-30 $-0.55
2012-06-30 $-0.61
2012-03-31 $-6.05
2011-12-31 $40.14
2011-09-30 $-6.64
2011-06-30 $-5.17
2011-03-31 $-7.48
2010-12-31 $0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.962B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00